Chipiron

Chipiron is a medical technology company focused on developing advanced MRI systems that enhance accessibility and affordability for healthcare providers and patients. Founded in 2020 in Paris, France, Chipiron specializes in innovative MRI technology. The company has engaged in four deals up to date, with its most recent funding round occurring on April 30, 2025. Chipiron raised EUR 14.

94 mn in Series A funding led by Blast. Club, with participation from EIC Accelerator, Bpifrance, European Innovation Council, and France 2030. The founder's details are currently unavailable. Chipiron specializes in the development of innovative MRI technology aimed at enhancing accessibility and affordability in medical imaging.

The company's flagship product is a pioneering light, open full-body MRI machine that operates utilizing ultra-low magnetic fields (<10 mT), effectively eliminating the need for complex infrastructure and high costs traditionally associated with MRI systems. This technology is designed to facilitate early diagnosis and image-guided non-invasive therapies for critical diseases, particularly cancer. Targeted end users include medical facilities, healthcare providers, and research institutions looking to implement widespread screening and advanced therapeutic applications. Chipiron's products are poised for commercial launch in various international markets, with a specific focus on the United States and Europe, where the demand for accessible MRI solutions is rapidly growing.

Chipiron's revenue model is structured around the direct sale of its advanced MRI systems and associated technologies to healthcare institutions and medical facilities. The company engages in B2B transactions, providing hospitals and diagnostic centers with an innovative MRI solution designed to improve diagnostic capabilities while reducing operational costs. Revenue generation occurs through the sale of these full-body MRI machines, complemented by ongoing service agreements and potential partnerships within the healthcare sector. Given the expected demand for Chipiron’s cost-effective imaging solutions, revenue streams may also include maintenance services and upgrades to their proprietary technology.

The company is actively pursuing investments, having secured significant funding to support product development and market entry, indicating strong backing for its revenue-generating capabilities. Chipiron plans to utilize the EUR 14. 94 mn raised in Series A funding to build its first clinical prototypes and prepare for clinical trials starting in 2026. The company aims to expand its market presence in the United States and Europe, where the demand for accessible MRI technology is increasing.

Chipiron is also focused on launching new products in the MRI technology space, enhancing its offerings to better serve healthcare providers and improve diagnostic care.